Big Tobacco moves into cannabis, synthetic CBD dangerously unregulated
Exec. sum of some points from the Jan & Feb. research for my cannabis column for ECigIntelligence, the premier data and analytics company…
Exec. sum of some points from the Jan & Feb. research for my cannabis column for ECigIntelligence, the premier data and analytics company for e-cigs, based in Barcelona.
Point 1: Following up on the trend noticed in last month’s column, Feb.’s column notes that tobacco companies are continuing to move into the cannabis space. Last month, it was vaping startups favouring cannabis instead of tobacco. This month it is Big Tobacco, which may be quietly moving into CBD.
Point 2: The fallout from AG Jeff Session’s memo, which unceremoniously stripped the Obama-era memo discouraging the prosecution of marijuana offenses, continues. San Francisco vowed to release people held on non-violent marijuana crimes, excluding those who sold to people under the age of 21.
Point 3: Synthetic CBD is under-regulated. An expert from John Hopkins explains the reason for the injuries noted by the Army Public Health Unit. In short, with synthetics, you never quite know what you’re getting. Consumers are given a bag of dry plants, sprayed with chemicals that approximate the effect of THC on the brain. They trade under many names and in many variations. They remain dangerously under-regulated. Or, in that expert’s words: “the consumer cannot trust the product.”
To see the actual column, visit ECigIntelligence.com.